ERAS vs. BDTX, MREO, RANI, TERN, HROW, NATR, ADCT, AMRN, ANRO, and PGEN
Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Black Diamond Therapeutics (BDTX), Mereo BioPharma Group (MREO), Rani Therapeutics (RANI), Terns Pharmaceuticals (TERN), Harrow (HROW), Nature's Sunshine Products (NATR), ADC Therapeutics (ADCT), Amarin (AMRN), Alto Neuroscience (ANRO), and Precigen (PGEN). These companies are all part of the "medical" sector.
Black Diamond Therapeutics (NASDAQ:BDTX) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 29.8% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Black Diamond Therapeutics received 22 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 63.33% of users gave Black Diamond Therapeutics an outperform vote while only 61.54% of users gave Erasca an outperform vote.
In the previous week, Erasca had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 8 mentions for Erasca and 7 mentions for Black Diamond Therapeutics. Erasca's average media sentiment score of 0.99 beat Black Diamond Therapeutics' score of -0.34 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.
Black Diamond Therapeutics presently has a consensus price target of $12.25, suggesting a potential upside of 100.49%. Erasca has a consensus price target of $7.83, suggesting a potential upside of 323.42%. Given Black Diamond Therapeutics' higher possible upside, analysts plainly believe Erasca is more favorable than Black Diamond Therapeutics.
Black Diamond Therapeutics' return on equity of -38.83% beat Erasca's return on equity.
Black Diamond Therapeutics has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics and Erasca tied by winning 7 of the 14 factors compared between the two stocks.
Get Erasca News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
